Results 21 to 30 of about 162,041 (218)

Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.

New England Journal of Medicine
BACKGROUND: C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis (MPGN) generally result in glomerular C3 deposition and irreversible kidney damage.
Delmas, Yahsou, Han, Seung Hyeok, Mastrangelo, Antonio, Kinnman, Nils, Szamosi, Johan, Wallace, Dean, Van De Kar, Nicole, Pickering, Matthew C, Nester, Carla M, Deschatelets, Pascal, Dixon, Bradley P, Bomback, Andrew S, VALIANT Trial Investigators Group, Fakhouri, Fadi, Zecher, Daniel, Kopyt, Nelson, DO, FASN, FACP, Ariceta, Gema, Vivarelli, Marina, Mizuno, Masashi, Abad-Franch, Lydia, Remuzzi, Giuseppe, Li, Li, López-Lázaro, Luis, Le Quintrec, Moglie, Isbel, Nicole, Gale, Daniel P, Licht, Christoph, Walker, Patrick D, Wang, Zhongshen, Greenbaum, Larry A, Francois, Cedric, Neves de Holanda, Maria Izabel   +31 more
core   +4 more sources

Recent insights into C3 glomerulopathy [PDF]

Nephrology Dialysis Transplantation, 2012
‘C3 glomerulopathy’ is a recent disease classification comprising several rare types of glomerulonephritis (GN), including dense deposit disease (DDD), C3 glomerulonephritis (C3GN) and CFHR5 nephropathy. These disorders share the key histological feature
Pickering, MC, Cook, HT, Barbour, TD
core   +5 more sources

Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy [PDF]

Kidney International Reports, 2023
Complement 3 glomerulopathy; Inflammatory kidney disease; IptacopanGlomerulopatia del complement 3; Malaltia inflamatòria del ronyó; IptacopanGlomerulopatía del complemento 3; Enfermedad inflamatoria del riñón; IptacopanIntroduction Complement 3 ...
Wong, Edwin, Le Quintrec, Moglie, Nester, Carla, Karras, Alexandre, Cavero Escribano, Teresa, Soler, María José, Lightstone, Liz, García-Carro, Clara   +7 more
core   +2 more sources

A 14-year-old boy with C3 glomerulopathy and Sjögren's syndrome identified by a school urinary screening program. [PDF]

Fukushima J Med Sci
C3 glomerulopathy (C3G) is a type of complement-associated glomerulopathy caused by a defect in the alternative complement pathway and is regarded as a rare disease.
Kawasaki Y, Ono A, Shirota J, Kume Y, Maeda R, Go H.   +5 more
europepmc   +2 more sources

Successful Management of C3 Glomerulopathy Recurrence Post-Kidney Transplantation with Iptacopan: A Case Report. [PDF]

Int J Mol Sci
C3 glomerulopathy (C3G) is the predominant cause of complement-mediated membranoproliferative glomerulonephritis and is considered a rare disorder caused by genetic or acquired dysregulation of the alternative complement pathway. There are no established
Troise D, Infante B, Mercuri S, Rossini M, Gesualdo L, Stallone G.   +5 more
europepmc   +2 more sources

Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases

Kidney Medicine
C3 glomerulopathy is a rare disease caused by fluid phase dysregulation of the alternative complement pathway. Currently, treatment depends on clinical and histological severity and includes nephroprotection, unspecific immunosuppression, and terminal ...
Víctor J. Escudero-Saiz, Ángela Gonzalez, Adriana García-Herrera, Ana B. Larque, Andrew S. Bomback, Laura Morantes, Marta Martínez-Chillarón, Júlia Ollé, Elena Guillén, Marc Xipell, Alicia Molina-Andújar, Diana Rodríguez, Elena Cuadrado, Judit Cacho, Carolt Arana, Núria Esforzado, Carla Bastida, Esteban Poch, Fritz Diekman, David Cucchiari, Luis F. Quintana, Miquel Blasco   +21 more
doaj   +2 more sources

C3 glomerulopathy associated with mycoplasma pneumoniae infection and positive IgA staining. [PDF]

BMC Nephrol
Patients with C3 glomerulopathy (C3G) often have a history of infection, which implies that infection may lead to abnormal activation of the complement alternative pathway (CAP) and induce the development of C3G.
Duan ZY, Li JJ, Cai GY, Wang S, Tang X, Hou W, Jiang L, Song Y.   +7 more
europepmc   +2 more sources

Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study

BMC Nephrology, 2023
Background C3 Glomerulopathy (C3G) is a rare glomerular disease caused by dysregulation of the complement pathway. Based on its pathophysiology, treatment with the monoclonal antibody eculizumab targeting complement C5 may be a therapeutic option. Due to
Thomas Welte, Frederic Arnold, Lukas Westermann, Felix A. Rottmann, Martin J. Hug, Elke Neumann-Haefelin, Athina Ganner   +6 more
doaj   +2 more sources

C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction

Case Reports in Nephrology and Dialysis, 2018
The advances in our understanding of the alternative pathway have emphasized that uncontrolled hyperactivity of this pathway causes 2 distinct disorders that adversely impact the kidney.
Ravneet Bajwa, John A. DePalma, Taimoor Khan, Anmol Cheema, Sheila A. Kalathil, Mohammad A. Hossain, Attiya Haroon, Anne Madhurima, Min Zheng, Ali Nayer, Arif Asif   +10 more
doaj   +2 more sources

Eculizumab in C3 Glomerulopathy: A Systematic Review of Therapeutic Efficacy and Clinical Outcomes [PDF]

Pharmaceutics
Background: C3 glomerulopathies (C3G), including dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), are rare kidney disorders driven by dysregulation of the alternative complement pathway.
Dominik Lewandowski, Mateusz Konieczny, Krzysztof Chrzanowski, Marta Jakubowska, Zuzanna Paryzek, Miłosz Miedziaszczyk, Ilona Idasiak-Piechocka   +6 more
doaj   +2 more sources